Printed from https://ideas.repec.org/s/spr/pharme9.html
Content
August 2006, Volume 24, Issue 8
- 751-765 A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials
by Darren Clayson & Diane Wild & Paul Quarterman & Isabelle Duprat-Lomon & Maria Kubin & Stephen Coons - 797-814 Costs of Inflammatory Bowel Disease in Germany
by Renee Stark & Hans-Helmut König & Reiner Leidl - 815-830 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
by Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette
June 2006, Volume 24, Issue 6
- 523-535 Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy
by Cornelis Boersma & Jarir Atthobari & Ron Gansevoort & Lolkje Jong-Van den Berg & Paul Jong & Dick Zeeuw & Lieven Annemans & Maarten Postma - 537-548 Healthcare Rationing in Spain
by Rosa Rodríguez-Monguió & Fernando Villar - 549-558 The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
by George Carides & Shahnaz Shahinfar & Erik Dasbach & William Keane & William Gerth & Charles Alexander & William Herman & Barry Brenner - 559-569 The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status
by Jarmo Hahl & Helena Hämäläinen & Tuula Simell & Olli Simell - 571-591 Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients
by Peter Schädlich & Michael Kentsch & Manfred Weber & Wolfgang Kämmerer & Josef Brecht & Vijay Nadipelli & Eduard Huppertz - 593-607 Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients
by George Dranitsaris & Mark Vincent & Mark Crowther - 609-621 Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?
by Lee-Yee Chong & Oh-Moh Chay & Li Shu-Chuen - 623-625 Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease
by Nick Bosanquet & Andrew Yeates - 625-626 The Authors’ Reply
by Colin Green & Joanna Picot & Emma Loveman & Andrea Takeda & Jo Kirby & Andrew Clegg
April 2006, Volume 24, Issue 4
- 387-400 A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy
by Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson
March 2006, Volume 24, Issue 3
- 265-280 Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias
by Jerrold Hill & Howard Fillit & Simu Thomas & Sobin Chang - 281-292 Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women
by Richard Milne & Kathy Heaton-Brown & Paul Hansen & David Thomas & Vernon Harvey & Alison Cubitt
December 2006, Volume 24, Issue 3
- 1-3 Medicaid Preferred Drug Lists: Cost Containment and Side Effects
by Alvin Headen - 5-25 The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003
by Frank Lichtenberg - 27-40 Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Statins and Antihypertensives?
by Jonathan Ketcham & Andrew Epstein - 41-53 Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods
by Alvin Headen & Neal Masia & Kirsten Axelsen - 55-63 Preferred Drug Lists and Medicaid Prescriptions
by Tamer Abdelgawad & Lisa Egbuonu-Davis - 65-78 Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence
by David Ridley & Kirsten Axelsen - 79-84 Per-patient-per-month Drug Costs in Medicare Part D Protected Classes
by Lisa Mucha & Neal Masia & Kirsten Axelsen
February 2006, Volume 24, Issue 2
- 171-191 The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia
by Rachael DiSantostefano & Andrea Biddle & John Lavelle - 193-205 Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries
by Antoine Lafuma & Antoine Brézin & Stefania Lopatriello & Klaus Hieke & Julia Hutchinson & Viviane Mimaud & Gilles Berdeaux
December 2006, Volume 24, Issue 2
- 1-3 Foreword
by Christopher-Paul Milne - 5-14 Health Reform in the US
by Robert Helms - 15-28 What Works and What Doesn’t Work Well in the US Healthcare System
by Harold Luft - 29-33 What an Informed Patient Means for the Future of Healthcare
by Ruth Parker - 35-54 The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine
by Desmond Sheridan & Jim Attridge - 55-57 Disease Management Programmes in Germany
by Stefan Felder - 59-68 Do Health-Related Labour Costs Weaken the Competitiveness of the Economy?
by Bertram Häussler & Thomas Ecker & Markus Schneider - 69-86 The Impact of Incremental Innovation in Biopharmaceuticals
by Ernst Berndt & Iain Cockburn & Karen Grépin - 87-94 Transatlantic Convergence with Respect to the Fourth Hurdle?
by Joshua Cohen - 95-99 Political Challenges for Healthcare Reform
by Lawrence Brown - 101-109 Lean Systems Approaches to Health Technology Assessment
by John Bridges - 111-119 Building a Competitive Insurance System
by Peter Zweifel - 121-122 Concluding Remarks
by Kenneth Kaitin
November 2006, Volume 24, Issue 1
- 1-3 Simulating the Real World of Antihyperglycaemic Therapies in Type 2 Diabetes
by Amanda Adler - 5-19 A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies
by Adrian Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart - 21-34 Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK
by Sophie Beale & Adrian Bagust & Arran Shearer & Alan Martin & Lisa Hulme - 35-48 Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany
by Arran Shearer & Adrian Bagust & Andreas Liebl & Oliver Schoeffski & Anita Goertz - 49-59 Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain
by Arran Shearer & Adrian Bagust & F. Ampudia-Blasco & Belén Martínez-Lage Álvarez & Isabel Pérez Escolano & Gonzalo París
December 2005, Volume 23, Issue 12
- 1193-1202 The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply
by Joseph DiMasi & Cherie Paquette - 1215-1227 Willingness to pay for inhaled insulin
by Hamid Sadri & Linda MacKeigan & Lawrence Leiter & Thomas Einarson
October 2005, Volume 23, Issue 10
- 995-1006 Pharmacological management of overactive bladder
by Denis Getsios & Wissam El-Hadi & Ingrid Caro & J. Caro - 1007-1020 The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden
by Peter Hertzman - 1057-1072 Eplerenone
by Katherine Croom & Greg Plosker
June 2005, Volume 23, Issue 6
- 543-566 The economics of topical immunomodulators for the treatment of atopic dermatitis
by William Abramovits & Mark Boguniewicz & Amy Paller & Diane Whitaker-Worth & Mary Prendergast & Michael Tokar & Kuo Tong - 619-637 Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
by Michael Spencer & Andrew Briggs & Ronald Grossman & Laureen Rance
October 2004, Volume 22, Issue 15
- 985-999 Economic Impact of Migraine and Other Episodic Headaches in France
by André Pradalier & Jean-Paul Auray & Abdelkader Hasnaoui & Kazem Alzahouri & Jean-François Dartigues & Gérard Duru & Patrick Henry & Michel Lantéri-Minet & Christian Lucas & Guy Chazot & Anne-François Gaudin
January 2003, Volume 21, Issue 1
- 1-11 Generic Clozapine
by Gordon Tse & Deborah Thompson & Ric Procyshyn - 13-38 Economic Evaluations of Varicella Vaccination Programmes
by Nancy Thiry & Philippe Beutels & Pierre Damme & Eddy Doorslaer - 39-48 Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies
by Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour - 49-60 Potential Costs and Effects of the National Service Framework for Coronary Heart Disease in the UK
by Venanzio Vella - 61-74 Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting
by W. Simons
May 2001, Volume 19, Issue 5
- 449-468 Hip Fracture Prevention
by Peter Vestergaard & Lars Rejnmark & Leif Mosekilde - 483-495 The Lifetime Cost of Bipolar Disorder in the US
by Charles Begley & John Annegers & Alan Swann & Christopher Lewis & Sharon Coan & William Schnapp & Lynda Bryant-Comstock - 497-512 Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension
by Peter Schädlich & Josef Brecht & Massimo Brunetti & Eva Pagano & Badrudin Rangoonwala & Eduard Huppertz
April 2000, Volume 17, Issue 4
- 319-324 The Importance of Achieving Additional Drug Benefits at a Reasonable Cost
by Nick Freemantle & James Mason - 325-330 Cost Effectiveness of Combination HIV Therapy
by Richard Moore - 331-338 Economic Burden of Irritable Bowel Syndrome
by Michael Camilleri & Donald Williams - 339-349 Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio
by Anthony O’Hagan & John Stevens & Jacques Montmartin - 351-360 Potential Savings in the Cost of Caring for Alzheimer’s Disease
by A. Hauber & Ari Gnanasakthy & Edward Snyder & Mohan Bala & Anke Richter & Josephine Mauskopf - 361-370 Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy
by Mark Sculpher & Michael Palmer & Anne Heyes - 371-382 Initial Treatment Choice in Depression
by Eric Edgell & Timothy Hylan & JoLaine Draugalis & Stephen Coons - 383-389 Cost Analysis of the Treatment of Schizophrenia in the UK
by Stephen Almond & Owen O’Donnell - 391-401 Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia
by Amnon Sonnenberg
December 1998, Volume 14, Issue 6
- 597-601 Are Mental Health Services Losing Out in the US Under Managed Care?
by Dale Johnson - 603-611 Thrombolysis, Stroke Units and Other Strategies for Reducing Acute Stroke Costs
by Theodore Wein & Susan Hickenbottom & Andrei Alexandrov - 613-627 A Review of Quality of Life in Alzheimer’s Disease
by Sam Salek & Melvyn Walker & Antony Bayer - 629-637 Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption
by Hind Hatoum & Sheldon Kong & Christopher Kania & Josephine Wong & Wallace Mendelson - 639-652 The Use and Cost of HIV Service Provision in England in 1996
by Eduard Beck & Keith Tolley & Amanda Power & Sundhiya Mandalia & Philippa Rutter & Junichi Izumi & Jeni Beecham & Alistair Gray & David Barlow & Philippa Easterbrook & Martin Fisher & John Innes & George Kinghorn & Bibhat Mandel & Anton Pozniak & Allan Tang & David Tomlinson & Ian Williams - 653-669 Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction
by Peter Schädlich & Eduard Huppertz & Josef Brecht - 671-684 Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
by Maureen Mölken & Eddy Doorslaer & M. Till - 685-690 Fosphenytoin
by Stephen Holliday & Paul Benfield & Greg Plosker - 691-708 Cyclosporin Microemulsion (Neoral®)†
by Allan Coukell & Greg Plosker - 709-709 A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe
by Linda MacKeigan - 710-711 The authors reply
by Sheila Hood & Lieven Annemans & Maureen Mölken - 711-712 Common Errors and Controversies in Pharmacoeconomic Analyses
by Javier Soto
June 1997, Volume 11, Issue 6
- 594-594 Erratum to Will Managed Care Work in Europe?
by E. Mossialos & P. Kanavos & B. Abel-Smith
March 1997, Volume 11, Issue 3
- 286-286 Erratum to Rational prescribing of antibacterials in ambulatory children
by JE Hoppe
February 1997, Volume 11, Issue 2
- 115-118 Economic Evaluation Techniques in Healthcare
by Alan Maynard - 119-125 The Role of the US Food and Drug Administration’s Patient Information Initiative in Cost-Effective Drug Therapy
by Stuart Nightingale & Thomas McGinnis - 126-138 The Economics of Osteoporosis and Its Prevention
by David Torgerson & David Reid - 139-158 The Economics of Pharmacotherapy for Diabetes Mellitus
by Bernardo Costa & Jaume Arroyo & Angels Sabaté - 159-168 Guidelines for Pharmacoeconomic Studies
by Joanna Siegel & George Torrance & Louise Russell & Bryan Luce & Milton Weinstein & Marthe Gold - 169-174 An Economic Evaluation of the Use of Granulocyte Colony-Stimulating Factor After Bone Marrow Transplantation in Children
by Nicholas Duncan & Margaret Hewetson & Ayad Atra & Gina Dick & Ross Pinkerton - 175-183 Differences in the Methodology and Data of Economic Evaluations of a Health Programme
by Xavier Badia & Gonzalo Nocea & Joan Rovira - 184-197 Terazosin
by Greg Plosker & Karen Goa